See more : Wan Hai Lines Ltd. (2615.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Intec Pharma Ltd (NTEC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intec Pharma Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
- Fab-Form Industries Ltd. (FBF.V) Income Statement Analysis – Financial Results
- Bank of Cyprus Holdings Public Limited Company (BOCH.L) Income Statement Analysis – Financial Results
- Zions Bancorporation, National Association (ZION) Income Statement Analysis – Financial Results
- Zhejiang Taifu Pump Co., Ltd (300992.SZ) Income Statement Analysis – Financial Results
- Elektrotim S.A. (ELT.WA) Income Statement Analysis – Financial Results
Intec Pharma Ltd (NTEC)
About Intec Pharma Ltd
Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was founded in 2000 and is based in Jerusalem, Israel.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.74M | 26.66M | 35.40M | 24.30M | 10.75M | 4.79M | 3.41M | 2.59M |
| General & Administrative | 7.09M | 8.29M | 7.93M | 5.12M | 3.07M | 2.75M | 2.59M | 2.74M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.09M | 8.29M | 7.93M | 5.12M | 3.07M | 2.75M | 2.59M | 2.74M |
| Other Expenses | 0.00 | -1.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 13.83M | 33.45M | 43.33M | 29.41M | 13.82M | 7.54M | 6.00M | 5.33M |
| Cost & Expenses | 13.83M | 33.45M | 43.33M | 29.44M | 13.85M | 7.56M | 6.02M | 5.36M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 15.00K | 23.00K | 17.00K | 16.00K | 15.37K | 23.00K | 24.41K |
| Depreciation & Amortization | 1.20M | 854.00K | 859.00K | 829.00K | 701.00K | 742.38K | 585.00K | 624.84K |
| EBITDA | -12.80M | -46.09M | -42.56M | -28.22M | -12.65M | -6.39M | -5.09M | -4.63M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -13.83M | -33.45M | -43.33M | -29.44M | -13.85M | -7.56M | -6.02M | -5.36M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -175.00K | -13.52M | -112.00K | 375.00K | 484.00K | 421.40K | 325.00K | 74.66K |
| Income Before Tax | -14.00M | -46.96M | -43.44M | -29.06M | -13.36M | -7.14M | -5.69M | -5.28M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 124.00K | 638.00K | 103.00K | 29.00K | 500.00K | 436.77K | 348.00K | 99.07K |
| Net Income | -14.13M | -47.60M | -43.54M | -29.09M | -13.36M | -7.14M | -5.69M | -5.28M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -14.30 | -112.74 | -111.67 | -131.79 | -93.38 | -73.35 | -94.39 | -97.75 |
| EPS Diluted | -14.30 | -112.74 | -111.67 | -131.79 | -93.38 | -73.35 | -94.39 | -97.75 |
| Weighted Avg Shares Out | 988.00K | 422.20K | 389.91K | 220.75K | 143.10K | 97.39K | 60.31K | 54.03K |
| Weighted Avg Shares Out (Dil) | 988.00K | 422.20K | 389.91K | 220.75K | 143.10K | 97.39K | 60.31K | 54.03K |
Last Week's 7 Biggest Cannabis Moves
INTEC PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Intec Pharma Ltd. - NTEC
Intec Pharma Announces Filing of 2020 Annual Report on Form 10-K
NTEC Stock Price Increases Over 80% Pre-Market: Why It Happened
Intec Pharma and Decoy Biosystems Announce Merger Agreement
Intec Pharma (NTEC) Stock Price Jumped Over 100%: Why It Happened
Intec Pharma News: Why NTEC Stock Is on Fire Today
9 Cannabis Stocks Making Moves During an Explosive U.S. Election Week
Virios Therapeutics Seeks IPO For Fibromyalgia Pain Treatment
Intec Pharma (NTEC) Receives a Hold from H.C. Wainwright
Source: https://incomestatements.info
Category: Stock Reports